Common Warts (Verruca Vulgaris)NCT07543926
New Treatment of Common Wart
A study testing PRF group and Vitamin D in people with Common Warts (Verruca Vulgaris), run by Sohag University at 1 site in Egypt.
Trial summary
this study aims to compare the efficacy and safety of platelet rich fibrin injection versus intralesional vitamin D injection in the treatmentof common warts. PRF, as an autologous biological material , may enhance tissue regeneration and immune response. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Common Warts (Verruca Vulgaris)
- What is being tested?
- PRF group and Vitamin D
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- 1 siteEgypt
- Study dates
- 6 Apr 2026to 30 Dec 2026
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- - Age more than or equal to 18 years
- Clinically and dermoscopically confirmed Common warts of both sex
- patient not receiving previous treatment at least one month before recruitment in our study
- Single or multiple lesions suitable for injection.
Who cannot join
- Chronic Systemic desise (DM , HTN , Autoimmune , immunosuppressive disorders eg , lupus , renal or hepatic failure ) or Hematologic Conditions (anemia : hemoglobin level below 10 g/dl , thrombocytopenia : platelet count below 150,000 /µL ) Infectious Diseases , Local bacterial or fungal infection at the lesions .
- Pregnancy, Lactation , patients who has hypersensitivity of vitamin D .
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Evaluation Of Intralesional Platelet-Rich Fibrin Versus Intralesional Vitamin D In Treatment Of Common Warts
this study aims to compare the efficacy and safety of platelet rich fibrin injection versus intralesional vitamin D injection in the treatmentof common warts. PRF, as an autologous biological material , may enhance tissue regeneration and immune response.
- Conditions
- Common Warts (Verruca Vulgaris)
- Being tested
- PRF group, Vitamin D
- Keywords
- PRF injection
- Medical subject headings
- Warts
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PRF groupBiological
intralesional PRF injection in common warts
Vitamin DDrug
intralesional vitamin D injection in common wart
| Study group | Role | What they receive |
|---|---|---|
| group 1 PRF injection | Active comparator | Not described Receives: Biological: PRF group |
| group 2 vitamin D injection | Active comparator | Not described Receives: Drug: Vitamin D |
What is being measured
The primary outcome is the main question the study is designed to answer.
treatment of common wart by PRF injection ( Mild response: < 50% reduction in lesion size , Moderate response: ≥ 50% reduction in lesion size , to measure the change in lesion size , is the patient satisfied or not )
treatment of common wart by intralesional injection of PRF
Measured: 1 session every 2 weeks for 3 months
changes in common warts after treatment by PRF (measuring complete clearance and recurrence of the lesions ,asking about patient satisfaction )
Measured: 6 months after the last session
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Apr 2026
- Study start6 Apr 2026 (estimated)
- Primary completion30 Nov 2026 (estimated)
- Study completion30 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Common Warts (Verruca Vulgaris)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 70 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Bassma Alaaeldin Mohamed, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07543926
- Sponsor's protocol ID
- Soh-Med-26-3-16MS
- Status last verified
- Mar 2026
- First submitted
- 1 Apr 2026
- Last updated
- 22 Apr 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No